Kol, Shahar2; Humaidan, Peter3; Al Humaidan, Peter Samir Heskjær4
1 Department of Clinical Medicine - Fertilitetsklinikken, Skive, Department of Clinical Medicine, Health, Aarhus University2 Department of Obstetrics and Gynecology, The IVF Unit, Rambam Medical Center, Haifa, Israel. email@example.com unknown4 Department of Clinical Medicine - Fertilitetsklinikken, Skive, Department of Clinical Medicine, Health, Aarhus University
The concept that a bolus of gonadotrophin-releasing hormone agonist (GnRHa) can replace human chorionic gonadotrophin (HCG) as a trigger of final oocyte maturation was introduced several years ago. Recent developments in the area strengthen this premise. GnRHa trigger offers important advantages, including virtually complete prevention of ovarian hyperstimulation syndrome (OHSS), the introduction of a surge of FSH in addition to the LH surge and finally the possibility to individualize luteal-phase supplementation based on ovarian response to stimulation. We maintain that the automatic HCG triggering concept should be challenged and that the GnRHa trigger is the way to move forward with thoughtful consideration of the needs, safety and comfort of our patients. Routinely, human chorionic gonadotrophin (HCG) is used to induce ovulation in fertility treatments. This approach deviates significantly from physiology and often results in insufficient hormonal support in early pregnancy and in ovarian hyperstimulation syndrome (OHSS). An alternative approach is to use a gonadotrophin-releasing hormone (GnRH) agonist which allows a more physiological trigger of ovulation and, most importantly, virtually eliminates the risk of OHSS. The current communication summarizes recent developments in the area and suggests future research efforts to enhance patients' safety and comfort.
Reproductive Biomedicine Online, 2013, Vol 26, Issue 3, p. 226-30